Anti-HDV IgM as a marker of disease activity in hepatitis delta

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Wranke, Anika ^a   Heidrich, Benjamin ^a   Ernst, Stefanie ^a   Serrano, Beatriz Calle ^a   Caruntu, Florin Alexandru ^c   Curescu, Manuela Gabriela ^d   Yalcin, Kendal ^e   Gürel, Selim ^f   Zeuzem, Stefan ^g   Erhardt, Andreas ^h   Lüth, Stefan ⁱ   Papatheodoridis, George V ^j   Bremer, Birgit ^a   Stift, Judith ^k   Grabowski, Jan ^a   Kirschner, Janina ^a   Port, Kerstin ^a   Cornberg, Markus ^a   Falk, Christine S ^a   Dienes, Hans Peter ^l   Hardtke, Svenja ^l   Manns, Michael P ^a,l   Yurdaydin, Cihan ^b   Wedemeyer, Heiner ^a,l,m   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ANKARA UNIVERSITY   (Turkey)

^c Institutul de Boli Cardiovasculare   (Romania)

^d Spitalul Clinic de Boli Infectioase   (Romania)

^e DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^f ULUDAG UNIVERSITY   (Turkey)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l HepNet Study House   (Germany)

^m German Center for Infection Research (DZIF) Partner Side HepNet Study House   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS DELTA ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; BIOLOGICAL MARKER; CYTOKINE; HEPATITIS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DELTA AGENT HEPATITIS; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; FOLLOW UP; HEPATITIS DELTA VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QUANTITATIVE ANALYSIS; BLOOD; CROSS-SECTIONAL STUDY; HEPATITIS B; HEPATITIS D; HEPATITIS D, CHRONIC; IMMUNOLOGY; LIVER; LIVER FUNCTION TEST; METABOLISM; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; COINFECTION; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B, CHRONIC; HEPATITIS D; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; IMMUNOGLOBULIN M; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84904991642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101002     Document Type: Article

References (26)

1. Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 7: 31-40.
2. Hughes SA, Wedemeyer H, Harrison PM (2011) Hepatitis delta virus. Lancet 378: 73-85.
3. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, et al. (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364: 322-331.
4. Heidrich B, Manns MP, Wedemeyer H (2013) Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 15: 31-38.
5. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, et al. (2010) Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 30: 430-437.
6. Heidrich B, Serrano BC, Idilman R, Kabacam G, Bremer B, et al. (2012) HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome. Liver Int 32: 1415-1425.
7. Rizzetto M (2010) Hepatitis D: Clinical features and therapy. Dig Dis 28: 139-143.
8. Borghesio E, Rosina F, Smedile A, Lagget M, Niro MG, et al. (1998) Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 27: 873-876. (Pubitemid 28103568)
9. Rizzetto M, Shih JW, Gocke DJ, Purcell RH, Verme G, et al. (1979) Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet 2: 986-990. (Pubitemid 10204619)
10. Farci P, Gerin JL, Aragona M, Lindsey I, Crivelli O, et al. (1986) Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. JAMA 255: 1443-1446. (Pubitemid 16167469)
11. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, et al. (2012) Anti-HDV immunoglobulin M testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon-alpha2a treatment. Antivir Ther 17: 305-312.
12. Grabowski J, Wedemeyer H (2010) Hepatitis delta: Immunopathogenesis and clinical challenges. Dig Dis 28: 133-138.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
14. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, et al. (2010) Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 48: 2022-2029.
15. Colloredo G, Bellati G, Leandro G, Colombatto P, Rho A, et al. (1996) Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. J Hepatol 25: 644-648. (Pubitemid 26373880)
16. Negro F, Giostra E, Rubbia-Brandt L, Mentha G, Colucci G, et al. (1998) IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. J Med Virol 56: 224-229. (Pubitemid 28458089)
17. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, et al. (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234. (Pubitemid 37011337)
18. Liu YJ (2005) IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23: 275-306.
19. Grabowski J, Yurdaydin C, Zachou K, Buggisch P, Hofmann WP, et al. (2011) Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int 31: 1395-1405.
20. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, et al. (2006) IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44: 1617-1625. (Pubitemid 44953667)
21. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, et al. (2011) Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53: 14-22.
22. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, et al. (2011) Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16: 915-924.
23. Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL (2013) Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 58: 898-903.
24. Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, et al. (2011) Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 85: 432-439.
25. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, et al. (2006) Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43: 100-107. (Pubitemid 43733596)
26. Nisini R, Paroli M, Accapezzato D, Bonino F, Rosina F, et al. (1997) Human CD4+ T-cell response to hepatitis delta virus: Identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 71: 2241-2251. (Pubitemid 27078605)